8-K - BJDX - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):August 15, 2025

****

BLUEJAY DIAGNOSTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

delaware	001-41031	47-3552922
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

360 Massachusetts Avenue, Suite 203

Acton, MA 01720

(Address of principal executive offices and zip code)

(844) 327-7078

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01	Other Events.

On August 15, 2025, the Board of Directors (the “Board”) of Bluejay Diagnostics, Inc. unanimously approved the following Board and committee Chair appointments, effective immediately: (i) Donald R. Chase as Chairperson of the Board (succeeding Douglas C. Wurth); (ii) Mr. Wurth as Chairperson of the Nominating and Corporate Governance Committee of the Board (succeeding Fred S. Zeidman), and (iii) Mr. Zeidman as Chairperson of the Compensation Committee of the Board (succeeding Mr. Chase). Mr. Chase remains Chairperson of the Audit Committee of the Board, and each of the three standing Board committees remain comprised of Messrs. Chase, Wurth and Zeidman. The foregoing Chair appointments were made as part of the Board’s periodic review and consideration of Board and committee governance assignments. Each of Messrs. Chase, Wurth and Zeidman have been determined by the Board to be independent under applicable Nasdaq listing rules, and to satisfy the independence criteria under Rule 10A-3 under the Securities Exchange Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Bluejay Diagnostics, Inc.
By:	/s/ Neil Dey
	Neil Dey
	President and Chief Executive Officer

Date: August 15, 2025